$BLUE
bluebird bio, Inc.

2017 Q1 Form 10-Q Financial Statement

#000156459017008384 Filed on May 03, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q4 2016 Q1
Revenue $6.832M $1.552M $1.499M
YoY Change 355.77% 5.51% -76.37%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $20.30M $16.20M $16.00M
YoY Change 26.88% 12.5% 119.18%
% of Gross Profit
Research & Development $55.00M $57.10M $41.91M
YoY Change 31.23% 59.94% 76.7%
% of Gross Profit
Depreciation & Amortization $2.840M $2.520M $2.280M
YoY Change 24.56% 23.53% 33.33%
% of Gross Profit
Operating Expenses $76.75M $73.89M $58.88M
YoY Change 30.34% 46.51% 88.29%
Operating Profit -$69.91M -$72.34M -$57.38M
YoY Change 21.84% 47.74% 130.2%
Interest Expense $1.556M -$600.0K -$1.000M
YoY Change -255.6% -146.15% 400.0%
% of Operating Profit
Other Income/Expense, Net -$355.0K $900.0K $961.0K
YoY Change -136.94% 800.0% 591.37%
Pretax Income -$68.71M -$71.40M -$56.42M
YoY Change 21.79% 50.95% 127.62%
Income Tax $0.00 -$100.0K -$145.0K
% Of Pretax Income
Net Earnings -$68.71M -$71.36M -$56.27M
YoY Change 22.1% 50.95% 127.03%
Net Earnings / Revenue -1005.74% -4598.2% -3754.1%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.684M -$1.874M -$1.526M
COMMON SHARES
Basic Shares Outstanding 40.84M 37.30M 36.93M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2016 Q4 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $634.1M $704.4M $553.1M
YoY Change 14.64% 36.01% 65.15%
Cash & Equivalents $216.0M $278.9M $192.6M
Short-Term Investments $418.1M $425.5M $360.5M
Other Short-Term Assets $3.285M $3.085M $7.900M
YoY Change -58.42% -48.58% 33.9%
Inventory
Prepaid Expenses $8.209M
Receivables
Other Receivables
Total Short-Term Assets $667.3M $724.2M $561.0M
YoY Change 18.95% 38.22% 64.6%
LONG-TERM ASSETS
Property, Plant & Equipment $181.7M $157.0M $96.60M
YoY Change 88.1% 89.99% 473.29%
Goodwill $13.13M $13.13M
YoY Change 0.0% 0.0%
Intangibles $20.69M $23.52M
YoY Change -15.38% -13.79%
Long-Term Investments $165.8M $180.5M $273.8M
YoY Change -39.44% -48.1% 103.72%
Other Assets $24.90M $22.68M $10.69M
YoY Change 133.02% 118.91% 725.81%
Total Long-Term Assets $405.3M $393.9M $417.7M
YoY Change -2.97% -17.66% 116.45%
TOTAL ASSETS
Total Short-Term Assets $667.3M $724.2M $561.0M
Total Long-Term Assets $405.3M $393.9M $417.7M
Total Assets $1.073B $1.118B $978.7M
YoY Change 9.59% 11.55% 83.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.800M $13.66M $3.136M
YoY Change 180.61% 115.72% 22.93%
Accrued Expenses $37.50M $49.50M $23.30M
YoY Change 60.94% 114.29% 54.3%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $72.60M $74.53M $38.97M
YoY Change 86.31% 84.63% -7.25%
LONG-TERM LIABILITIES
Long-Term Debt $147.6M $120.1M $74.40M
YoY Change 98.39% 94.02%
Other Long-Term Liabilities $37.00M $120.0K $58.80M
YoY Change -37.07% -49.37% 22088.68%
Total Long-Term Liabilities $184.6M $120.0K $133.2M
YoY Change 38.59% -49.37% 50164.15%
TOTAL LIABILITIES
Total Short-Term Liabilities $72.60M $74.53M $38.97M
Total Long-Term Liabilities $184.6M $120.0K $133.2M
Total Liabilities $257.2M $248.7M $172.2M
YoY Change 49.36% 63.78% 190.3%
SHAREHOLDERS EQUITY
Retained Earnings -$577.7M
YoY Change 83.87%
Common Stock $407.0K
YoY Change 10.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $815.4M $869.4M $806.5M
YoY Change
Total Liabilities & Shareholders Equity $1.073B $1.118B $978.7M
YoY Change 9.59% 11.55% 83.34%

Cashflow Statement

Concept 2017 Q1 2016 Q4 2016 Q1
OPERATING ACTIVITIES
Net Income -$68.71M -$71.36M -$56.27M
YoY Change 22.1% 50.95% 127.03%
Depreciation, Depletion And Amortization $2.840M $2.520M $2.280M
YoY Change 24.56% 23.53% 33.33%
Cash From Operating Activities -$75.30M -$69.11M -$36.77M
YoY Change 104.79% 108.85% 52.19%
INVESTING ACTIVITIES
Capital Expenditures $26.02M -$13.02M $3.894M
YoY Change 568.31% 278.49% 236.85%
Acquisitions
YoY Change
Other Investing Activities $21.57M -$119.5M $68.34M
YoY Change -68.44% -45.1% -135.63%
Cash From Investing Activities -$4.450M -$132.6M $64.45M
YoY Change -106.9% -40.07% -133.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $3.040M $639.0K
YoY Change 375.74% -74.07%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 16.87M 239.8M 640.0K
YoY Change 2535.94% 23406.86% -73.98%
NET CHANGE
Cash From Operating Activities -75.30M -69.11M -36.77M
Cash From Investing Activities -4.450M -132.6M 64.45M
Cash From Financing Activities 16.87M 239.8M 640.0K
Net Change In Cash -62.88M 38.10M 28.32M
YoY Change -322.03% -115.04% -113.19%
FREE CASH FLOW
Cash From Operating Activities -$75.30M -$69.11M -$36.77M
Capital Expenditures $26.02M -$13.02M $3.894M
Free Cash Flow -$101.3M -$56.09M -$40.66M
YoY Change 149.17% 89.17% 60.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 us-gaap Other Assets Current
OtherAssetsCurrent
3285000
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3085000
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1201000
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
961000
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-68712000
CY2016Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-56419000
CY2016Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-145000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-68712000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.68
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40836000
CY2017Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-101000
CY2016Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1319000
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-68813000
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54955000
CY2017Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2016Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
700000
CY2017Q1 blue Fair Value Of Contingent Consideration Non Cash
FairValueOfContingentConsiderationNonCash
1433000
CY2016Q1 blue Fair Value Of Contingent Consideration Non Cash
FairValueOfContingentConsiderationNonCash
1013000
CY2017Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2844000
CY2016Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2283000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
11481000
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
10143000
CY2017Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
838000
CY2016Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
868000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3105000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2271000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3257000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2195000
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-13318000
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
211000
CY2017Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3969000
CY2016Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
9222000
CY2017Q1 blue Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
462000
CY2016Q1 blue Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
234000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-75303000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-36766000
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
26024000
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3894000
CY2017Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
82940000
CY2016Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
28175000
CY2017Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
104510000
CY2016Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
96515000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-4454000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
64446000
CY2017Q1 blue Proceeds From Reimbursement Of Tenant Improvements For Financing Lease Obligation
ProceedsFromReimbursementOfTenantImprovementsForFinancingLeaseObligation
13831000
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3040000
CY2016Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
639000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
16871000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
639000
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-62886000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
28319000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
164269000
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
192588000
CY2017Q1 blue Assets Acquired Under Financing Lease Obligation
AssetsAcquiredUnderFinancingLeaseObligation
1269000
CY2016Q1 blue Assets Acquired Under Financing Lease Obligation
AssetsAcquiredUnderFinancingLeaseObligation
12513000
CY2017Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
5971000
CY2016Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1086000
CY2017Q1 blue Tenant Improvements Under Financing Lease Included In Tenant Improvements Receivable
TenantImprovementsUnderFinancingLeaseIncludedInTenantImprovementsReceivable
12687000
CY2017Q1 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Description of the business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bluebird bio, Inc. (the &#8220;Company&#8221; or &#8220;bluebird&#8221;) was incorporated in Delaware on April&#160;16, 1992, and is headquartered in Cambridge, Massachusetts. The Company researches, develops, manufactures and plans to commercialize gene therapies for the treatment of severe genetic diseases and cancer. Since its inception, the Company has devoted substantially all of its resources to its research and development efforts relating to its product candidates, including activities to manufacture product candidates, conduct clinical studies of its product candidates, perform preclinical research to identify new product candidates and provide general and administrative support for these operations.</p></div>
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1492000
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
11000
CY2016Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
4479000
CY2017Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
781000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
643000
CY2017Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14284000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12444000
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:2.27%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the <font style="color:#000000;">reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially</font> from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas, among others: subsequent fair value estimates used to assess potential impairment of long-lived assets, including goodwill and intangible assets, financing lease obligation, contingent consideration, stock-based compensation expense, accrued expenses, revenue and income taxes.</p></div>
CY2017Q1 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2017Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6251000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11296000
CY2017Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
6059000
CY2017Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
196004000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
169399000
CY2017Q1 blue Accrued Goods And Services
AccruedGoodsAndServices
29538000
CY2016Q4 blue Accrued Goods And Services
AccruedGoodsAndServices
34275000
CY2017Q1 blue Accrued License And Milestone Fees
AccruedLicenseAndMilestoneFees
285000
CY2016Q4 blue Accrued License And Milestone Fees
AccruedLicenseAndMilestoneFees
2464000
CY2017Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1393000
CY2017Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
1992-04-16
CY2017Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2017Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
584507000
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
606481000
CY2017Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
17000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
40000
CY2017Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
656000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
578000
CY2017Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
583868000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
605943000
CY2017Q1 us-gaap Additional Cash And Cash Equivalent Related Text
AdditionalCashAndCashEquivalentRelatedText
Three months or less
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4640000
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4434000
CY2013Q2 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P9Y
CY2013Q2 blue Area Of Leased Space
AreaOfLeasedSpace
43600
CY2013Q2 blue Lease Amendment Effective Month And Year
LeaseAmendmentEffectiveMonthAndYear
2014-06
CY2013Q2 blue Additional Lease Space Agreement
AdditionalLeaseSpaceAgreement
9900
CY2013Q2 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
200000
CY2014Q4 us-gaap Operating Leases Rent Expense Contingent Rentals
OperatingLeasesRentExpenseContingentRentals
300000
CY2013Q2 blue Landlord Contribution For Leasehold Improvements
LandlordContributionForLeaseholdImprovements
7800000
CY2013Q2 blue Letter Of Credit Related To New Lease Agreement
LetterOfCreditRelatedToNewLeaseAgreement
1300000
CY2017Q1 blue Letter Of Credit Related To New Lease Agreement
LetterOfCreditRelatedToNewLeaseAgreement
600000
CY2013Q2 blue Lease Starting Date
LeaseStartingDate
2013-06-03
CY2017Q1 blue Lease Termination Date
LeaseTerminationDate
2017-04-12
CY2016Q4 blue Contractual Obligation Agreement Period
ContractualObligationAgreementPeriod
P5Y
CY2016Q4 blue Contractual Obligation Agreement Renewal Period
ContractualObligationAgreementRenewalPeriod
P3Y
CY2016Q4 blue Contractual Obligation Fees
ContractualObligationFees
3000000
CY2016Q4 blue Contractual Obligation Advance Fees Payment
ContractualObligationAdvanceFeesPayment
2000000
CY2016Q4 blue Contractual Obligation Fees Payable
ContractualObligationFeesPayable
1000000
CY2016Q4 us-gaap Maintenance Costs
MaintenanceCosts
9800000
CY2017Q1 blue Contractual Obligation Termination Description
ContractualObligationTerminationDescription
The Company may terminate this agreement with six months’ notice and a one-time termination fee prior to July 1, 2018, or twelve months’ notice and a one-time termination fee thereafter.
CY2017Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1500000
CY2017Q1 blue Tenant Improvement Costs Received
TenantImprovementCostsReceived
7800000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
1600000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2000000
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11481000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3735000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
696000
CY2017Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
181000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
47000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4203000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2070000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4203000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
52.17
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
76.37
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
15.18
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
88.88
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
57.35
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
42.63
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
57.35
CY2017Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2700000

Files In Submission

Name View Source Status
0001564590-17-008384-index-headers.html Edgar Link pending
0001564590-17-008384-index.html Edgar Link pending
0001564590-17-008384.txt Edgar Link pending
0001564590-17-008384-xbrl.zip Edgar Link pending
blue-10q_20170331.htm Edgar Link pending
blue-20170331.xml Edgar Link completed
blue-20170331.xsd Edgar Link pending
blue-20170331_cal.xml Edgar Link unprocessable
blue-20170331_def.xml Edgar Link unprocessable
blue-20170331_lab.xml Edgar Link unprocessable
blue-20170331_pre.xml Edgar Link unprocessable
blue-ex311_7.htm Edgar Link pending
blue-ex312_6.htm Edgar Link pending
blue-ex321_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending